FingerPTChinKJSemenovaEAIntravitreal anti-VEGF therapy for macular radiation retinopathy: a 10-year study.Eur J Ophthalmol201626(1)60–66
2.
FingerPTRadiation therapy for orbital tumors: concepts, current use, and ophthalmic radiation side effects.Surv Ophthalmol200954(5)545–568
3.
FingerPTChinKJYuGPPatelNSPalladium-103 for Choroidal Melanoma Study Group.Risk factors for cataract after palladium-103 ophthalmic plaque radiation therapy. Int J Radiat Oncol Biol Phys201180(3)800–806
4.
FingerPTTumour location affects the incidence of cataract and retinopathy after ophthalmic plaque radiation therapy.Br J Ophthalmol200084(9)1068–1070
5.
FingerPTChinKJYuGPPalladium-103 for Choroidal Melanoma Study Group.Risk factors for radiation maculopathy after ophthalmic plaque radiation for choroidal melanoma. Am J Ophthalmol2010149(4)608–615
6.
FingerPTChinKJTenaLBA five-year study of slotted eye plaque radiation therapy for choroidal melanoma: near, touching, or surrounding the optic nerve.Ophthalmology20121192415–422
7.
YousefYAFingerPTLack of radiation maculopathy after palladium-103 plaque radiotherapy for iris melanoma.Int J Radiat Oncol Biol Phys201283(4)1107–1112
8.
FingerPTMukkamalaSKIntravitreal anti-VEGF bevacizumab (Avastin) for external beam related radiation retinopathy.Eur J Ophthalmol201121(4)446–451
9.
PaulT Finger assignee. Anti-VEGF Treatment for Radiation Induced Vasculopathy.United States of America, June 30th, 2009.
10.
FingerPTChinKAnti-vascular endothelial growth factor bevacizumab (avastin) for radiation retinopathy.Arch Ophthalmol2007125(6)751–756
11.
FingerPTAnti-VEGF bevacizumab (Avastin) for radiation optic neuropathy.Am J Ophthalmol2007143(2)335–338
